ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

The Future of AI and Drug Development: Insights from Absci’s Sean McClain and Andreas Busch

Автор: ARK Invest

Загружено: 2024-11-01

Просмотров: 3506

Описание: In this episode of FYI, Brett Winton and Charles Roberts sit down with Sean McClain, CEO and founder of Absci, and Andreas Busch, Absci's Chief Innovation Officer, to explore how AI is transforming drug discovery and development, particularly in the biologic space. Sean shares how Absci is using AI to tackle the design problem in drug discovery, unlocking new possibilities for "undruggable" targets. Andreas provides insights into the challenges of translating these advancements into real-world therapies, drawing from his deep experience in Big Pharma. Together, they discuss the role of AI in reducing the time and cost of developing new therapies and its potential to reshape the pharmaceutical landscape.

Key Points From This Episode:
● The role of AI in addressing previously "undruggable" targets like GPCRs and ion channels.
● How Absci’s AI-driven approach has shifted from synthetic biology to designing antibodies and biologics for drug discovery.
● The importance of leveraging partnerships with pharma companies like AstraZeneca and Merck to unlock novel biology.
● Andreas Busch’s transition from Big Pharma to Absci, emphasizing how smaller biotech companies attract top talent and foster innovation.
● AI’s role in shortening drug development timelines and reducing costs, allowing companies like Absci to develop differentiated assets faster.
● The blend of best-in-class and first-in-class strategies in Absci’s portfolio, balancing risks in novel biology and proven therapeutic areas.
● How AI models are used to design antibodies with specific affinities and predict drug candidates, a first in antibody drug design.
● The critical role of integrating domain expertise, such as Andreas’s experience in drug development, into AI-driven drug discovery.
● Insights on the future of AI in biology, predicting targets, epitopes, and potential breakthroughs in drug development.
● The importance of talent and culture in building cutting-edge biotech companies.


More FYI Podcasts: https://ark-invest.com/podcasts/

To learn more about ARK: https://arkinv.st/ARKInvest

For more updates, follow us on:
Twitter: https://arkinv.st/3corDiY
LinkedIn: http://arkinv.st/1f7AiVX
Facebook: http://arkinv.st/3r4EDOU
Instagram: http://arkinv.st/39td8bO

Disclosure: http://arkinv.st/39rzF94

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
The Future of AI and Drug Development: Insights from Absci’s Sean McClain and Andreas Busch

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

ABS-201 Androgenetic Alopecia KOL Seminar

ABS-201 Androgenetic Alopecia KOL Seminar

Humanoid Robots Capability Over Cost | The Brainstorm EP 78

Humanoid Robots Capability Over Cost | The Brainstorm EP 78

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Bonus Episode: How Is Trump Planning to ‘Run’ Venezuela? (With Anne Applebaum) | The David Frum Show

Bonus Episode: How Is Trump Planning to ‘Run’ Venezuela? (With Anne Applebaum) | The David Frum Show

Redefining Medicine: Nobel Laureate David Baker On AI In Drug Discovery

Redefining Medicine: Nobel Laureate David Baker On AI In Drug Discovery

Absci on AI Accelerated Drug Discovery: Advanced Insights S2E3

Absci on AI Accelerated Drug Discovery: Advanced Insights S2E3

AMD's CEO Wants to Chip Away at Nvidia's Lead | The Circuit with Emily Chang

AMD's CEO Wants to Chip Away at Nvidia's Lead | The Circuit with Emily Chang

Novartis CEO discusses how AI will impact drug development

Novartis CEO discusses how AI will impact drug development

Лауреат Нобелевской премии по физике: квантовый скачок, изменивший всё — Джон Мартинис

Лауреат Нобелевской премии по физике: квантовый скачок, изменивший всё — Джон Мартинис

Почему Андрей Карпати чувствует себя

Почему Андрей Карпати чувствует себя "отстающим" (и что это значит для вашей карьеры)

Absci and AMD Announce Collaboration to Accelerate the Future of AI Drug Discovery

Absci and AMD Announce Collaboration to Accelerate the Future of AI Drug Discovery

The Tesla of Appliances? Impulse Labs’ CEO Sam D’Amico

The Tesla of Appliances? Impulse Labs’ CEO Sam D’Amico

Демис Хассабис: Будущее ИИ, симуляция реальности, физика, игры | Лекс Фридман Подкаст #475

Демис Хассабис: Будущее ИИ, симуляция реальности, физика, игры | Лекс Фридман Подкаст #475

Były szef agencji wywiadu o zatrzymaniu Nicolasa Maduro  || płk Piotr Krawczyk - didaskalia#167

Były szef agencji wywiadu o zatrzymaniu Nicolasa Maduro || płk Piotr Krawczyk - didaskalia#167

How Tempus Is Using AI To Transform Diagnostics With Eric Lefkofsky

How Tempus Is Using AI To Transform Diagnostics With Eric Lefkofsky

Ark's Cathie Wood on DeepSeek, AI, Crypto, Trump

Ark's Cathie Wood on DeepSeek, AI, Crypto, Trump

Машинное обучение в разработке лекарств в Bayer Pharmaceuticals: от моделей к молекулам

Машинное обучение в разработке лекарств в Bayer Pharmaceuticals: от моделей к молекулам

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Evolving Narratives in the Crypto Space with Andreas M. Antonopoulos

Evolving Narratives in the Crypto Space with Andreas M. Antonopoulos

Sean McClain and Frank Tate at Built with Biology 2022

Sean McClain and Frank Tate at Built with Biology 2022

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]